Abivax (ABVX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Abivax (ABVX) is a FR-listed Healthcare company in Biotechnology with a market capitalization of $9.6B, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Abivax's market cap?
Abivax (ABVX) has a market capitalization of approximately $9.6B, trading at
What is Abivax's P/E ratio?
Abivax's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 17.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Abivax?
Abivax runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Abivax pay a dividend?
Abivax does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Abivax financially healthy?
Abivax carries a debt-to-equity ratio of 0.10x and a current ratio of 8.75x, with a market beta of -0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Abivax a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Abivax (ABVX) the key facts are: market cap $9.6B, 52-week range 62.5-148.83. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Abivax's full fundamentals live
Get Abivax's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.